Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
Jerry Sadoff, Mathieu Le Gars, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anna Marit de Groot, Jeroen Stoop, Sarah Tete, Wim Van Damme, Isabel Leroux-Roels, Pieter-Jan Berghmans, Murray Kimmel, Pierre Van Damme, Jan De Hoon, William Smith, Kathryn Stephenson, Dan Barouch, Stephen De Rosa, Kristen Cohen, Juliana McElrath, Emmanuel Cormier, Gert Scheper, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Johan Van Hoof, Hanneke Schuitemaker
doi: https://doi.org/10.1101/2020.09.23.20199604
